A unique and reliable approach for inducing NK cells from iPSCs (iNK) in a completely feeder-free environment was designed in this study. After 35 days, the cell proportion of CD3-CD56 + iNK Cells ...

Shares of ImmunityBio (IBRX) gained more than 3% in pre-market trading on Friday, after the pharmaceutical firm announced on Friday the completion of key manufacturing engineering programs supporting ...

Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to ...

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according ...

ANKL is a rare and aggressive type of blood cancer affecting a type of white blood cell called natural killer (NK) cells. In ANKL, the NK cells are abnormal and multiply out of control, crowding out ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...